MSC-ex reduced YAP-activated LOXL2 expression by releasing miR-27b-3p, inhibiting liver fibrosis, which indicates that MSC-ex may represent a new strategy for treating liver fibrosis. Here, LOXL2 is linked to Hepatic fibrosis.